Clinical trial Recruiting at 1 site Observational Ages 18 and up

Understanding the prognosis and biomarkers of infective endocarditis

Official title: Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR): a National Multi-center, Retrospective-prospective, Cohort Study Initiated by the Investigators

Run by First Affiliated Hospital Xi'an Jiaotong University · NCT05965362 · Data updated 2026-11-12

This study is trying to learn more about how infective endocarditis progresses and what factors affect it by looking at patients and their biomarkers to improve diagnosis and treatment.

More Infective Endocarditis trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorFirst Affiliated Hospital Xi'an Jiaotong University
Academic / other
Locations1 site (Xi'an, Shaanxi)
StatusRecruiting
StartedMay 9, 2024
Main results expectedDecember 31, 2028
Study endsDecember 31, 2028
Registry record updatedJuly 12, 2024
Trial IDNCT05965362 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with clinically confirmed infective endocarditis.

Probably not a fit

Patients who refuse to sign the informed consent form or have serious systemic diseases that prevent them from tolerating biological sample acquisition may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a clinical cohort of patients with infective endocarditis to observe the natural prognosis and influencing factors during the disease's progression and regression. Utilizing multi-omics technology, the study seeks to uncover the prognostic value of various biomarkers associated with the condition. The findings are expected to provide new insights into the pathogenesis, clinical diagnosis, and treatment strategies for infective endocarditis.

Why it matters

Potential benefit: If successful, this study could lead to improved early detection and targeted treatment options for patients with infective endocarditis.

How similar studies have gone: While the approach of using multi-omics technology in this context is relatively novel, similar studies have shown promise in understanding other infectious diseases.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with clinically confirmed infective endocarditis

Exclusion Criteria:

* Patients refuse to sign informed consent form
* Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples

Where it's running

  • First Affiliated Hospital of Xian Jiantong University
    Xi'an, Shaanxi, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.